<DOC>
	<DOCNO>NCT00470067</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin hydrochloride liposome carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give doxorubicin hydrochloride liposome together carboplatin work treat patient recurrent , stage III , stage IV primary endometrial cancer .</brief_summary>
	<brief_title>Doxorubicin Hydrochloride Liposome Carboplatin Treating Patients With Recurrent , Stage III , Stage IV Primary Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate response rate patient recurrent stage III IV primary endometrial carcinoma treat doxorubicin hydrochloride liposome carboplatin . Secondary - Determine progression-free survival patient treat regimen . - Determine overall survival patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive doxorubicin hydrochloride liposome IV 1 hour day 1 carboplatin IV 30 minute day 1 . Treatment repeat every 28 day 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 6 month every 3 month thereafter . PROJECTED ACCRUAL : A total 37 patient accrue study .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary endometrial carcinoma meeting 1 follow criterion : Stage III IV disease accord FIGO stag criterion Recurrent disease consider incurable Measurable disease A lesion within previously irradiate field acceptable measurable disease clear progression since completion radiotherapy PATIENT CHARACTERISTICS : GOG performance status 02 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Creatinine &lt; 2.5 mg/dL OR creatinine clearance ≥ 60 mL/min ALT AST ≤ 1.5 time upper limit normal ( ULN ) ( 3 time ULN presence liver metastasis ) Alkaline phosphatase ≤ 1.5 time ULN ( 3 time ULN presence liver metastasis ) Total bilirubin ≤ 1.5 time ULN ( 3 time ULN presence liver metastasis ) Not pregnant nursing Left ventricular ejection fraction ( LVEF ) ≥ 50 % MUGA scan ECHO No history severe hypersensitivity reaction doxorubicin hydrochloride liposome No invasive malignancy ( i.e. , breast cancer ) within past 5 year except nonmelanoma skin cancer No cardiac disease , include follow : Myocardial infarction within past 6 month NYHA class IIIV heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmia Clinically significant pericardial disease Acute ischemic active conduction system abnormalities ECHO PRIOR CONCURRENT THERAPY : No prior chemotherapy No prior cancer therapy would contraindicate study treatment No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
</DOC>